A phase 2 randomized study of ramucirumab (IMC 1121B; RAM) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM) (CP12-0604/NCT00533702) Meeting Abstract
| Authors: | Carvajal, R.; Thompson, J.; Gordon, M.; Lewis, K.; Pavlick, A.; Wolchok, J.; Rojas, P.; Schwartz, J.; Bedikian, A. |
| Abstract Title: | A phase 2 randomized study of ramucirumab (IMC 1121B; RAM) with or without dacarbazine (DTIC) in patients (pts) with metastatic melanoma (MM) (CP12-0604/NCT00533702) |
| Meeting Title: | 37th Congress of the European Society for Medical Oncology (ESMO) |
| Journal Title: | Annals of Oncology |
| Volume: | 23 |
| Issue: | Suppl. 9 |
| Meeting Dates: | 2012 Sep 28-Oct 2 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2012-09-01 |
| Start Page: | ix363 |
| Language: | English |
| ACCESSION: | WOS:000309409002053 |
| PROVIDER: | wos |
| PUBMED: | 23012731 |
| DOI: | 10.1093/annonc/mds404 |
| Notes: | Meeting Abstract: 1115PD -- "Source: Wos" |
Altmetric
Citation Impact
BMJ Impact Analytics
